Artia Global Partners LP Trevi Therapeutics, Inc. Transaction History
Artia Global Partners LP
- $631 Billion
- Q3 2025
A detailed history of Artia Global Partners LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Artia Global Partners LP holds 1,999,702 shares of TRVI stock, worth $22.7 Million. This represents 2.9% of its overall portfolio holdings.
Number of Shares
1,999,702
Previous 1,311,840
52.43%
Holding current value
$22.7 Million
Previous $7.18 Billion
154.99%
% of portfolio
2.9%
Previous 1.73%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
173Shares Held
119MCall Options Held
629KPut Options Held
1.22M-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million7.39% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Viking Global Investors LP5.13MShares$58.1 Million0.13% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...